ReviewInternational journal of clinical oncology2014
Radiobiological basis of SBRT and SRS.
Review in International journal of clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial
Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 185 citations in OpenAlex.
- Treatment progress of spinal metastatic cancer: a powerful tool for improving the quality of life of the patients.Journal of orthopaedic surgery and research · 2023Pooled it
- Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review.Radiation oncology (London, England) · 2022Pooled it
- Efficacy and safety of single-fraction stereotactic body radiotherapy (SBRT) for the curative treatment of extracranial primary Tumors: A collaborative systematic review on behalf of the SBRT Focus Group of the European Society for Radiotherapy & Oncology (ESTRO).Clinical and translational radiation oncology · 2027Review
- Basis and prospects of radiotherapy combined with high-intensity focused ultrasound ablation (Review).Oncology letters · 2026Review
- Hyperbaric Oxygen Therapy for Late Radiation-Induced Duodenal Toxicity After Stereotactic Body Radiotherapy in a Patient with Cholangiocellular Carcinoma: A Unique Case Report.Current oncology (Toronto, Ont.) · 2026Article
- Historical Review of the Role of Indirect Cell Death in High-Dose Per Fraction Radiation Therapy.Advances in radiation oncology · 2026Review
- Article
- Stereotactic body radiation therapy for oligometastatic melanoma: a real-world study of the ESTRO/EORTC nomenclature.Radiation oncology (London, England) · 2026Article
- Effect of combining targeted therapies or chemotherapy with stereotactic radiosurgery (SRS) on the prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC).Journal of neuro-oncology · 2025Article
- The evolution of stereotactic radiosurgery for vestibular schwannomas: recent evidence and outcomes.Journal of neuro-oncology · 2025Review
- Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors.Nature biotechnology · 2025Article
- Review
- Robotic Stereotactic Ablative Radiotherapy for Patients with Early-Stage Lung Cancer: Results of an Interim Analysis.Cancers · 2024Article
- How Does the Number of Brain Metastases Correlate With Normal Brain Exposure in Single-Isocenter Multitarget Multifraction Stereotactic Radiosurgery.Advances in radiation oncology · 2024Article
- Article
- Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.The clinical respiratory journal · 2024Article
- Dynamic contrast-enhanced magnetic resonance imaging parameter changes as an early biomarker of tumor responses following radiation therapy in patients with spinal metastases: a systematic review.Radiation oncology journal · 2023Article
- Review
- Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma.International journal of radiation oncology, biology, physics · 2023Article
- Epidemiology, management, and treatment outcomes of metastatic spinal melanoma.World neurosurgery: X · 2023Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) have been demonstrated to be highly effective for a variety of tumors. However, the radiobiological principles of SBRT and SRS have not yet been clearly defined. It is well known that newly formed tumor blood vessels are fragile and extremely sensitive to ionizing radiation. Various lines of evidence indicate that irradiation of tumors with high dose per fraction, i.e. >10 Gy per fraction, not only kills tumor cells but also causes significant damage in tumor vasculatures. Such vascular damage and ensuing deterioration of the intratumor environment then cause ischemic or indirect/secondary tumor cell death within a few days after radiation exposure, indicating that vascular damage plays an important role in the response of tumors to SBRT and SRS. Indications are that the extensive tumor cell death due to the direct effect of radiation on tumor cells and the secondary effect through vascular damage may lead to massive release of tumor-associated antigens and various pro-inflammatory cytokines, thereby triggering an anti-tumor immune response. However, the precise role of immune assault on tumor cells in SBRT and SRS has not yet been clearly defined. The "4 Rs" for conventional fractionated radiotherapy do not include indirect cell death and thus 4 Rs cannot account for the effective tumor control by SBRT and SRS. The linear-quadratic model is for cell death caused by DNA breaks and thus the usefulness of this model for ablative high-dose SBRT and SRS is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.